VistaGen Therapeutics Inc

NASDAQ:VTGN   3:59:53 PM EDT
2.75
+0.09 (+3.38%)
Earnings Announcements

Vistagen Therapeutics Inc Reports FY 2021 Loss Per Share $0.49

Published: 06/29/2021 21:28 GMT
VistaGen Therapeutics Inc (VTGN) - Vistagen Therapeutics Inc Reports FY Total Revenue $1.1 Million .
Vistagen Therapeutics Inc Reports FY 2021 Loss per Share $0.49 .
Vistagen - Palisade-1 Phase 3 Trial Underway to Evaluate Ph94b for Rapid-onset Acute Treatment of Anxiety in Adults With Social Anxiety Disorder.
Vistagen - at March 31, 2021, Co Had Cash & Cash Equivalents of About $103.1 Million.
Revenue is expected to be $0.39 Million
Adjusted EPS is expected to be -$0.05

Next Quarter Revenue Guidance is expected to be $0.39 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.